Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Triclabendazole (also known as CGA-89317; CGA89317; EGA-230B; Fasinex; NVP-EGA-230; Egaten) is a benzimidazole-based anthelmintic and fasciolicidal agent that acts as a tubulin inhibitor by binding to tubulin and impairing the intracellular transport mechanisms, thus interfering with protein synthesis.
ln Vitro |
Both MCF-7 and MDA-MB-231 cells are cytotoxic to triclabendazole (20-320 μM, 24-48 h) [1]. MCF-7 and MDA-MB-231 cells undergo apoptosis when exposed to triclabendazole (40–160 μM, 24 h) [1]. The cytotoxicity of trimetazole (0.97-500 μM, 48-72 h) on macrophages is minimal [3]. Proflagellated cells' cell cycle stages are significantly altered by triclabendazole (45.67 μM, 72 h) [3].
|
||
---|---|---|---|
ln Vivo |
In nude mice implanted with MDA-MB-231 cells, trimethobenzole (20–100 mg/kg, intraperitoneal injection, twice weekly for 2 weeks) has antitumor activity [1].
|
||
Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: MCF-7 and MDA-MB-231 cells Tested Concentrations: 20 μM, 40 μM, 80 μM, 160 μM, 320 μM, Incubation Duration: 24 h, 48 h Experimental Results: Dramatically diminished the metabolism activity. Apoptosis Analysis[1] Cell Types: MCF-7 and MDA-MB-231 cells Tested Concentrations: 40 μM, 80 μM, 160 μM Incubation Duration: 24 h Experimental Results: Dramatically induced apoptosis at 160 μM. Up-regulated the expression of Bax and down-regulated the expression of Bcl-2. Activated and cleaved caspase-8 and caspase-9 in a dose-dependent manner. |
||
Animal Protocol |
|
||
References |
[1]. Yan L, et al. Triclabendazole induces pyroptosis by activating caspase-3 to cleave GSDME in breast cancer cells [J]. Frontiers in Pharmacology, 2021, 12: 670081.
[2]. Devine C, et al. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole [J]. Veterinary parasitology, 2012, 184(1): 37-47. [3]. Borges B S, et al. In vitro anti-Leishmania activity of triclabendazole and its synergic effect with amphotericin B [J]. Frontiers in Cellular and Infection Microbiology, 2023, 12: 1044665. |
Molecular Formula |
C14H9CL3N2OS
|
|
---|---|---|
Molecular Weight |
359.66
|
|
CAS # |
68786-66-3
|
|
Related CAS # |
Triclabendazole-d3;1353867-93-2;Triclabendazole-13C,d3
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
ClC1C([H])=C2C(=C([H])C=1OC1C([H])=C([H])C([H])=C(C=1Cl)Cl)N=C(N2[H])SC([H])([H])[H]
|
|
InChi Key |
NQPDXQQQCQDHHW-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)
|
|
Chemical Name |
6-Chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7804 mL | 13.9020 mL | 27.8040 mL | |
5 mM | 0.5561 mL | 2.7804 mL | 5.5608 mL | |
10 mM | 0.2780 mL | 1.3902 mL | 2.7804 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.